Biopharmx Corp (NASDAQ:BPMX) was up 4.6% during trading on Friday . The company traded as high as $0.21 and last traded at $0.21. Approximately 1,108,406 shares traded hands during mid-day trading, an increase of 5% from the average daily volume of 1,056,650 shares. The stock had previously closed at $0.20.
A number of equities research analysts recently commented on BPMX shares. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Biopharmx Corp in a report on Wednesday, September 13th. Maxim Group reiterated a “buy” rating and issued a $1.50 price objective (down from $3.00) on shares of Biopharmx Corp in a research note on Wednesday, September 13th.
The firm’s 50-day moving average price is $0.28 and its 200-day moving average price is $0.43. The firm’s market capitalization is $16.34 million.
Biopharmx Corp (NASDAQ:BPMX) last released its quarterly earnings results on Wednesday, September 13th. The company reported ($0.06) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Equities research analysts predict that Biopharmx Corp will post ($0.24) earnings per share for the current fiscal year.
In other news, major shareholder Franklin Resources Inc acquired 250,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were purchased at an average cost of $0.34 per share, for a total transaction of $85,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Hedge funds have recently made changes to their positions in the company. Virtu KCG Holdings LLC raised its position in shares of Biopharmx Corp by 366.2% during the 2nd quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after purchasing an additional 395,424 shares during the period. Vanguard Group Inc. raised its position in shares of Biopharmx Corp by 324.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after purchasing an additional 1,478,338 shares during the period. Finally, Vivo Capital LLC raised its position in shares of Biopharmx Corp by 10.0% during the 2nd quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after purchasing an additional 1,282,052 shares during the period.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
What are top analysts saying about Biopharmx Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biopharmx Corp and related companies.